SCHEMBL3139488

SCHEMBL3139488

COc1cc2c(cc1F)NC(=O)CNC2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.42
TDP2 O95551 1/20 0.42
KDM4E B2RXH2 1/20 0.40
NCOA1 Q15788 2/20 0.39
NCOA3 Q9Y6Q9 2/20 0.39
GSK3B P49841 4/20 0.38
CCNB2 O95067 3/20 0.38
CDK1 P06493 3/20 0.38
CCNB1 P14635 3/20 0.38
CDK5 Q00535 3/20 0.38
CDK5R1 Q15078 3/20 0.38
CCNB3 Q8WWL7 3/20 0.38
TLK2 Q86UE8 2/20 0.36
EGFR P00533 1/20 0.35
HTT P42858 1/20 0.35
DAPK3 O43293 1/20 0.35
NTRK1 P04629 1/20 0.35
PIM1 P11309 1/20 0.35
FLT3 P36888 1/20 0.35
ROCK1 Q13464 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5489309 0.89 KDM4E (0.47) KDM4EGSK3BCCNB2CDK1CCNB1
SCHEMBL25414934 0.86 TSHR (0.40) TDP2NCOA1NCOA3GAATSHR
SCHEMBL29338764 0.86 TSHR (0.40) TDP2NCOA1NCOA3GAATSHR
SCHEMBL4780926 0.80 CLK4 (0.47) TDP2KDM4ENCOA1NCOA3GSK3B
SCHEMBL16832315 0.78 ALDH1A1 (0.51) CDK2TDP2TLK2EGFRRET
SCHEMBL13827240 0.76 CLK4 (0.47) TDP2KDM4ENCOA1NCOA3GSK3B
SCHEMBL20698336 0.74 PDE3B (0.51) GSK3BCCNB2CDK1CCNB1CDK5
SCHEMBL3148940 0.74 PDE3B (0.63) CDK2KDM4EGSK3BCCNB2CDK1
SCHEMBL14361898 0.73 CYP11B1 (0.42) CREBBPPDE3BPDE3A
SCHEMBL26768115 0.72 GSK3B (0.47) CDK2TDP2KDM4ENCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687620-B2 [1,4]diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents WYETH LLC (US) 2010-03-30 US disclosed
EP-1497293-B1 (1,4)DIAZEPINO(6,7,1-IJ)QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS WYETH CORP (US) 2008-06-11 EP disclosed
US-20070004707-A1 [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents RAMAMOORTHY P S 2007-01-04 US disclosed
US-7129237-B2 [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents WYETH (US) 2006-10-31 US disclosed
EP-1497293-A1 (1,4)DIAZEPINO(6,7,1-IJ)QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS Wyeth (US) 2005-01-19 EP disclosed
US-20040009970-A1 [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents WYETH 2004-01-15 US disclosed
WO-2003091250-A1 [1,4]DIAZEPINO[6,7,1-IJ]QUINOLINE DERIVATIVES AS ANTI PSYCHOTIC AND ANTIOBESITY AGENTS WYETH (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004707-A1 [1,4]Diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents HTR2C, HTR1A, HTR1D CDK2 2587/4885TDP2 2543/4885KDM4E 733/4885
US-20040009970-A1 [1,4]Diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents HTR2C, HTR1A, HTR1D CDK2 2661/4885TDP2 2588/4885KDM4E 944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.